Kidney Transplant for C3G & IC-MPGN: Eligibility, Risks & New Therapies

For individuals grappling with C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN), kidney transplantation offers a potential path toward improved quality of life, though it’s not a cure. These rare, chronic diseases progressively damage the kidneys’ filtering mechanisms, sometimes leading to kidney failure and the need for dialysis. While transplantation can circumvent the challenges of dialysis – a life-sustaining but demanding treatment – it carries its own set of complexities, particularly the significant risk of disease recurrence.

Understanding the Transplant Process

The journey to a potential kidney transplant begins with a comprehensive evaluation at a transplant center. This assessment determines whether a patient is healthy enough to undergo the procedure and is approved for the national waiting list. A donor, either from a recently deceased individual who chose organ donation or a living person with two healthy kidneys, is required. The evaluation process isn’t limited to the recipient. potential living donors also undergo rigorous testing to ensure their health and suitability. This includes a thorough review of physical and mental health, blood tests, imaging, cancer screenings, and infectious disease testing. Financial considerations are also addressed, with transplant teams often connecting patients with counselors to navigate insurance coverage and potential costs.

If deemed a suitable candidate, a patient is added to the national waiting list. But, having a living donor significantly accelerates the process, allowing the transplant to proceed once both donor and recipient are prepared. It’s critical to note that patients with C3G and IC-MPGN follow the same evaluation procedures as other transplant candidates, but they face a heightened risk of the disease returning after the transplant.

The Risks of Recurrence and What’s Being Done

Estimates suggest a substantial risk of recurrence following transplantation, ranging from 45% for IC-MPGN to as high as 89% for C3G. This recurrence can occur relatively quickly, within the first few months post-transplant, and often leads to eventual failure of the new kidney in about half of cases. The underlying immune system dysfunction that causes these diseases doesn’t disappear with a new kidney; it can continue to attack the transplanted organ.

However, recent advancements offer a glimmer of hope. Newer medications called complement inhibitors are showing promising results in clinical trials. These drugs target the complement cascade – a series of reactions within the immune system – to prevent the abnormal protein buildup that causes inflammation and kidney damage. Iptacopan (Fabhalta) received FDA approval in March 2025 for C3G, and pegcetacoplan (Empaveli) followed in July 2025 for both C3G and IC-MPGN. While studies demonstrate their ability to improve kidney function and reduce damage, their long-term impact on transplant recipients is still being investigated.

Immunosuppression: A Lifelong Commitment

Regardless of recurrence risk, managing the immune system is crucial after a kidney transplant. The body naturally identifies the new kidney as foreign and attempts to reject it. To prevent this, patients must take immunosuppressant medications for life, or as long as the transplanted kidney functions. These medications weaken the immune system, but still allow it to defend against serious infections.

The process typically involves two phases: induction therapy, a strong dose of antirejection medication administered intravenously before and immediately after surgery, and maintenance therapy, oral medications taken long-term. A common protocol, used in over 95% of U.S. Renal transplants, includes thymoglobulin for induction, followed by tacrolimus (Prograf), mycophenolate mofetil (CellCept), and prednisone for maintenance, according to Stanley Jordan, MD, director of nephrology and medical director of the kidney transplant program at Cedars-Sinai Medical Center in Los Angeles.

Monitoring and Long-Term Outlook

Post-transplant care involves diligent monitoring for signs of organ rejection and disease recurrence. Periodic kidney biopsies can detect recurrence even before symptoms appear, allowing for prompt intervention. While the outlook remains challenging, the advent of complement inhibitors is improving outcomes. Clinical trials are ongoing to explore new potential inhibitors and therapies.

Despite the risks, kidney transplantation significantly improves life expectancy compared to remaining on dialysis – by a factor of six, according to Dr. Jordan. Yasir A. Qazi, MD, a transplant nephrologist at Providence St. Joseph Hospital in Orange, California, emphasizes that transplantation offers a better quality of life and more years of life.

Potential Complications and Risks

Like all major surgeries, kidney transplants carry inherent risks, including infection (due to immunosuppression), surgical complications like pain or bleeding, and organ rejection. Infections are relatively common within the first three months post-transplant, often urinary tract infections, due to the weakened immune system. Rejection can occur at any time, though it’s more frequent in the first year. There are different types of rejection – hyperacute (rare, due to incompatibility), acute (happening soon after transplant), and chronic (developing gradually over years) – each with varying causes and treatments.

It’s important to remember that a transplant addresses the *symptom* – kidney failure – but not the *cause* of C3G or IC-MPGN.

What Comes Next: Research and Emerging Therapies

The field of C3G and IC-MPGN transplantation is rapidly evolving. Researchers are actively investigating the role of complement inhibitors in preventing recurrence and preserving kidney function. Ongoing clinical trials are evaluating new inhibitors and experimental therapies. The focus is on understanding the underlying mechanisms of these diseases and developing targeted treatments to improve long-term outcomes for transplant recipients. Further research is needed to determine the optimal utilize of complement inhibitors and to identify biomarkers that can predict recurrence risk and guide treatment decisions.